NCT01324258View on ClinicalTrials.gov

Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

January 24, 2011

Primary Completion Date

July 8, 2013

Study Completion Date

July 8, 2013

Conditions

Solid Tumours

Interventions

DRUG

GSK1120212

Part1 and Part2

DRUG

Gemcitabine

Part2

Trial Locations (2)

589-8511

GSK Investigational Site, Osaka

181-8611

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01324258 - Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter